News Archives - CenExel

CenExel CNS Opens Center in Los Alamitos, California

by dave | Nov 29, 2022

Los Alamitos, November 29, 2022 /GlobeNewswire/ — CenExel CNS announces the grand opening of the newest clinical research facility in Los Alamitos, California. CenExel CNS has been operating clinical research centers in the area since 2000, and this site will be the...

CenExel Creates Clinical Sciences Business Unit

by dave | Nov 15, 2022

Salt Lake City, November 15, 2022 /GlobeNewswire/ — CenExel announces a new Clinical Sciences business unit, composed of early phase and translational medicine scientists, plus the broader network of CenExel therapeutic experts and key opinion leaders (KOLs),...

Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers.

by chill | Nov 9, 2022

Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry led-study in subjects with schizophrenia and healthy volunteers.

CenExel Psychedelic Facilitators Undergoing Premier Certification Training

by chill | Nov 3, 2022

Our Clinical Sciences team, comprised of Dr. Larry Ereshefsky, Dr. Brett English, Dr. Robert Litman, along with Principal Investigators Dr. Djouher Hough, and Dr. Haig Goenjian, have developed fit for purpose go-to-clinic strategies encompassing pharmacology, regulatory, and protocol-development consultation services, as well as meticulous clinical trial execution.

Placebo-Control Reminder Script

by chill | Oct 31, 2022

General medicine studies are not immune to the placebo effect, where 30-40% of patients report improved subjective and objective outcomes in general medical studies (Hrobjartsson & Gotzsche, 2001). The high placebo response has been shown to be increasing as time progresses (Kemp et al., 2010; Loebel et al., 2010; Rief et al., 2009; Tuttle et al., 2015), with such ramifications as several pharma companies reducing or closing their psychiatric as well as general medicine R&D, increased costs for drug development, more inconclusive and failed trials, and delays in the development of new medications (Alphs et al., 2012).

Brandy Isaacks Joins CenExel as Vice President of Project Management & Scientific Affairs

by dave | Oct 19, 2022

Salt Lake City, October 20, 2022 /GlobeNewswire/ — CenExel announced that Brandy Isaacks has joined their team as Vice President of Project Management and Scientific Affairs. Brandy’s responsibilities will include providing project management coordination and support...

Update on COVID-19

To: Our Sponsors, CROs, Patients, and Employees

At CenExel Clinical Research, our top priorities are the safety and health of our patients and employees. For our Centers of Excellence to provide the highest quality of clinical research, we established and maintain a COVID-19 Task Force with representatives from every Center. The Task Force is charged with continuous monitoring of the pandemic and providing guidance and communication.

Our clinical operations continue, and we have implemented the following additional safety measures:

Enhanced screening of everyone entering any of our facilities before they are admitted into our offices or clinical areas
Reinforced internal communication regarding the COVID-19 situation, CDC and SHRM recommendations, digital team meetings, and the importance of using sick leave for anyone who has signs, symptoms, or recent exposure to someone with suspected or diagnosed COVID-19
Additional cleaning and disinfecting materials provided through our clinic and office areas
Cross-training and preparations for contingency plans if key staff need to stay home

We will continue to monitor the current situation, coordinate with the proper authorities, and update our policies and procedures as needed to ensure the safety of our patients and employees.

News at CenExel